MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

Exacerbations of Osteoarthritis: 7.5 mg/day (half a 15 mg tablet); if necessary, in the absence of improvement, the dose may be increased to 15 mg/day. MOVALIS is used to treat the symptoms of osteoarthritis. This disease mainly affect the joints causing pain and swelling. Skin reactions. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of Movalis. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Movalis should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation , and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).

If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous. Side effects The efficacy of meloxicam in treating the symptoms of osteoarthritis has been confirmed in several clinical studies. Two clinical studies of six months duration were performed in patients with osteoarthritis of the hip or knee. In the first study, the efficacy of meloxicam 15 mg (n = 306) and piroxicam 20 mg (n = 149) were found to be comparable, using as efficacy endpoints improvement in overall pain, pain on movement, global efficacy, change in duration of inactivity and change in quality of life score. In the second study, the efficacy of meloxicam 7.5 mg (n = 169) was found to be comparable to that of diclofenac 100 mg SR (n = 167) using similar endpoints. GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.

Poliartrită reumatoidă: 15 mg/zi. În funcţie de răspunsul terapeutic, doza poate fi redusă la 7,5 mg/zi. Spondilită anchilopozantă: 15 mg/zi. The dose of Movalis in patients with endstage renal failure on haemodialysis should not exceed 7.5 mg/day (see Pharmacology, Renal impairment). No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 20 mL/min) nor in patients with mild to moderate hepatic impairment. In nondialysed patients with severe renal impairment Movalis is contraindicated (see Contraindications). disfuncţie renală, care poate evolua în insuficienţă renală cu oligo-hidramnios; mama şi nou-născutul, la sfârşitul sarcinii, la: Diuretics. Treatment with NSAIDs is associated with the potential for acute renal insufficiency in patients who are dehydrated. Patients receiving Movalis and diuretics should be adequately hydrated and be monitored for renal function prior to initiating treatment.

Meloxicam crosses the placental barrier. There are no adequate, well controlled studies in pregnant women. Meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. scaderea numarului plachetelor sanguine (trombocitopenie). Acest reactii adverse pot conduce la o crestere a riscului de aparitie a infectiilor si a unor simptome, cum ar fi vanatai sau sangerare a nasului; Use in patients being treated with corticosteroids. Movalis cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. Higher doses of Movalis (22.5 mg and greater) have been associated with an increased risk of serious gastrointestinal tract (GIT) adverse events, therefore, the daily dose of Movalis should not exceed 15 mg. The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg (half a 15 mg tablet) per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day.Movalis is available as tablets containing 7.5 mg and 15 mg of meloxicam. The excipients are sodium citrate dihydrate, lactose monohydrate, microcrystalline cellulose, povidone, crospovidone, colloidal anhydrous silica, magnesium stearate. Pharmacology

NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal functionPatients with signs and/or symptoms suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Movalis. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc), Movalis should be discontinued. Elimination. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the faeces and urine. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and faeces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Movalis orodispersible tablets after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking). Litiu: AINS cresc concentraţiile plasmatice de litiu (prin scăderea excreţiei renale a litiului), care poate atinge valori toxice. Nu se recomandă administrarea concomitentă de litiu şi AINS. Dacă este necesară această asociere trebuie monitorizată cu atenţie concentratia litiului plasmatic atunci când se iniţiază, se modifică sau se întrerupe tratamentul cu meloxicam.